The "golden hour" and acute brain ischemia: Presenting features and lytic therapy in >30 000 patients arriving within 60 minutes of stroke onset

Stroke

Volumn 41, Issue 7, 2010, Pages 1431-1439

  Saver, Jeffrey L ^a   Smith, Eric E ^b   Fonarow, Gregg C ^a   Reeves, Mathew J ^c   Zhao, Xin ^d   Olson, Daiwai M ^d   Schwamm, Lee H ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

acute care; acute stroke; acute therapy; emergency medical services; emergency medicine; stroke care; stroke delivery; therapy; thrombolysis; thrombolytic therapy

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE DELIVERY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STROKE; TIME; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; FACTUAL DATABASE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; COHORT STUDIES; DATABASES, FACTUAL; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; MIDDLE AGED; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77954174189     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.583815     Document Type: Article

References (28)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
2. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40:2079-2084.
3. Saver JL. Time is brain-quantified. Stroke. 2006;37:263-266.
4. Marler JR, Winters Jones P, Emr M, The National Institute of Neurological Disorders and Stroke. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. Bethesda, Md: National Institute of Neurological Disorders and Stroke; 1997.
5. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vonhooren G; SITS-MOST Investigators. Thrombol-ysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
6. Erratum in Lancet. 2007; 369:826.
7. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. Can Med Assoc J. 2005;172:1307-1312.
8. Evenson KR, Foraker RE, Morris DL, Rosamond WD. A comprehensive review of prehospital and in-hospital delay times in acute stroke care. Int J Stroke. 2009;4:187-199.
9. George MG, Tong X, McGruder H, Yoon P, Rosamond W, Winquist A, Hinchey J, Wall HK, Pandey DK; Centers for Disease Control and Prevention (CDC). Paul Coverdell National Acute Stroke Registry Surveillance: four states, 2005-2007. MMWR Surveill Summ. 2009;58:1-23.
10. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. J Am Med Assoc. 2000;283:1145-1150.
11. Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, Ellrodt G, Cannon CP, Liang L, Peterson E, Labresh KA. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119:107-115.
12. Reeves MJ, Fonarow GC, Zhao X, Smith EE, Schwamm LH. Quality of care in women with ischemic stroke in the GWTG program. Stroke. 2009;40:1127-1133.
13. LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the 'Get With The Guidelines' program. Arch Intern Med. 2008;168:411-417.
14. American Hospital Association. American Hospital Association Hospital Statistics 2007. Chicago, Ill: American Hospital Association; 2007.
15. Awareness of stroke warning symptoms-13 states and the District of Columbia, 2005. MMWR Morb Mortal Wkly Rep. 2008;57:481-485.
16. Stansbury JP, Jia H, Williams LS, Vogel WB, Duncan PW. Ethnic disparities in stroke: epidemiology, acute care, and postacute outcomes. Stroke. 2005;36:374-386.
17. Schumacher HC, Bateman BT, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, Pile-Spellman J. Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004. Ann Emerg Med. 2007;50:99-107.
18. Kreuter MW, Wray RJ. Tailored and targeted health communication: strategies for enhancing information relevance. Am J Health Behav. 2003;27(suppl 3):S227-S232
19. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 2005;64:654-659.
20. Laloux P, Thijs V, Peeters A, Desfontaines P. Obstacles to the use of intravenous tissue plasminogen activator for acute ischemic stroke: is time the only barrier? Acta Neurol Belg. 2007;107:103-107.
21. ESO Executive Committee, ESO Writing Committee. European Stroke Organization Guideline Update, January 2009 [online]. Available at: http://www.eso-stroke.org/pdf/ESO%20Guidelines-update-Jan-2009.pdf.
22. Lindsay PBP, Bayley MMD, Hellings CB, Hill MMMD, Woodbury EBMHA, Phillips SM. Canadian best practice recommendations for stroke care (updated 2008). Can Med Assoc J. 2008;179:S1-S25.
23. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
24. NINDS t-PA Stroke Study Investigators. NINDS t-PA Stroke Study Data Set (on CD-ROM). 2006. Available for purchase at: www.ntis.gov
25. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. Stroke. 1997;28: 1530-1540.
26. Tveiten A, Mygland A, Ljostad U, Thomassen L. Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre. Emerg Med J. 2009;26:324-326
27. A systems approach to immediate evaluation and management of hyperacute stroke: experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Stroke. 1997; 28:1530-1540.
28. Schwamm LH, Pancioli A, Acker JE III, Goldstein LB, Zorowitz RD, Shephard TJ, Moyer P, Gorman M, Johnston SC, Duncan PW, Gorelick P, Frank J, Stranne SK, Smith R, Federspiel W, Horton KB, Magnis E, Adams RJ; American Stroke Association's Task Force on the Development of Stroke Systems. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the development of stroke systems. Stroke. 2005;36:690-703. (Pubitemid 40344183)